NCT06688656View on ClinicalTrials.gov

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2028

Conditions
Lung Cancer
Interventions
DRUG

Pemetrexed 500 mg/m2

1\. Pemetrexed: 500mg/m² on Day 1, Q3W, administered via intravenous infusion for a total of 3 cycles.

DRUG

carboplatin

AUC=5 on Day 1, Q3W，administered via intravenous infusion for a total of 3 cycles.

DRUG

Sintilimab

Sintilimab, 200mg, administered via intravenous infusion on the 3rd day of each cycle, Q3W, for a total of 3 cycles.

Trial Locations (1)

200030

241, West Huaihai Road, Shanghai, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER